Octapharma

Octapharma

Fabricación de productos farmacéuticos

Lachen, Switzerland 53.523 seguidores

Our passion drives us to provide new health solutions advancing human life

Sobre nosotros

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs nearly 12,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology and Critical Care. Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 195 plasma donation centres across Europe and the US. Octapharma has 40 years of experience in patient care. Check our community guidelines: https://bit.ly/3M8ioml

Sitio web
http://www.octapharma.com
Sector
Fabricación de productos farmacéuticos
Tamaño de la empresa
Más de 10.001 empleados
Sede
Lachen, Switzerland
Tipo
De financiación privada
Fundación
1983
Especialidades
Plasma Fractionation, Haematology, Immunotherapy y Critical Care

Ubicaciones

Empleados en Octapharma

Actualizaciones

  • Ver la página de empresa de Octapharma, gráfico

    53.523 seguidores

    From September 26–28, experts gathered in the stunning Åland archipelago to discuss the latest in VWD diagnosis and management. This historic location, tied to the origins of VWD research, provided a meaningful backdrop for insightful discussions.   Read the full event report on our website to learn more about the advancements shared at this significant meeting: https://bit.ly/3BpejtT   #vonwillebranddisease #vwd

  • In 1999, we established our global headquarters in Lachen, Switzerland, starting with just 20 employees.   Since then, our team has grown to 120 employees, representing over 25 nationalities and reflecting 25 years of development and success. With its picturesque lakeside setting and strategic position in Europe, Lachen, along with our dedicated global, clinical R&D, and Swiss market teams, continues to play a vital role in our vision to provide new health solutions advancing human life.

  • Octapharma Dessau’s commitment to high standards in business practices and employee experience has earned it a place as a regional finalist in the 2024 "Großer Preis des Mittelstands" (Grand Prize for Small and Medium-Sized Businesses). This recognition positively impacts Dessau-Roßlau as a business location, highlighting that this is the first time in recent years a company from the region has been a finalist for the award. Read the story here: https://bit.ly/3YBoMdi

    • No hay descripción de texto alternativo para esta imagen
  • Advancements in artificial intelligence within the healthcare sector are showing significant potential to revolutionise and expedite the diagnosis and treatment of patients with primary immunodeficiencies. Join Manish Butte, Elie Haddad, and Helen Leavis to learn about the latest scientific advances and practical applications at the Octapharma symposium at #ESID2024 on Friday, October 18, at 12:15 CET. See the details here: https://bit.ly/4eYIYfM

  • Primary immunodeficiencies are rare and present with a diverse range of symptoms, often leading to significant delays in diagnosis and treatment. These delays aggravate both mortality and morbidity. Recent advancements in artificial intelligence (#AI) within healthcare have shown great promise in revolutionising and accelerating the diagnosis and care of patients with primary immunodeficiencies. Join us at #ESID2024 on Friday, October 18 at 12:15 CET to explore the latest scientific breakthroughs and practical applications: https://bit.ly/4eYIYfM

    • No hay descripción de texto alternativo para esta imagen
  • Karin, with over 1,400 donations, and Mike, with over 1,200, are dedicated plasma donors at Octapharma. For both, what began as a simple act has evolved into a deep connection with their community and a commitment to saving lives. Their stories are a testament to the life-saving power of plasma donations and the incredible bonds formed within the Octapharma Plasma community. This week (October 7-11), we celebrate International Plasma Awareness Week and honor donors like Karin and Mike—the heart of our lifesaving mission. #IPAW2024

  • World Myositis Day on September 21 brings attention to a group of rare autoimmune diseases known collectively as myositis.   These diseases often lead to muscle weakness, pain, and fatigue, severely impacting mobility. Everyday tasks like climbing stairs or lifting arms above the head can become challenging.   Given the complexity of these symptoms, it’s crucial to raise awareness about myositis not only among the general public but also within the medical and research communities. Increased understanding can lead to earlier diagnosis, more effective treatments, and improved quality of life for those affected by myositis.   Learn more about the symptoms, diagnosis, and treatment of myositis here: https://bit.ly/3TDs2D5

  • The next patient case from our Clinical Practice online series goes live on One Source on Monday, September 23 at 17:00 CET.   Join us and Natascha Marquardt for an interactive session where we will discuss bleeding management strategies using FVIII treatment in a patient with acquired haemophilia A. We look forward to answering any questions you may have.   Sign up for the session here: https://bit.ly/3MLFu40   The event is for healthcare professionals only.

    • No hay descripción de texto alternativo para esta imagen

Páginas similares

Buscar empleos